A post hoc analysis of the STOP-or-NOT trial demonstrates that preoperative cardiovascular risk stratification does not influence the outcomes of continuing versus discontinuing renin-angiotensin system inhibitors before major noncardiac surgery, supporting a flexible approach to perioperative management.